NO20051695L - Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer - Google Patents

Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer

Info

Publication number: NO20051695L
Authority: NO; Norway
Prior art keywords: spirocondensed; quinazolinones; novel; phosphodiesterase inhibitors; compounds
Prior art date: 2002-09-17

Application number

NO20051695A

Other languages

English (en)

Norwegian (no)

Inventor

Fabrice Vergne

Chrystelle Mendes

Pierre Gerard Ducrot

Patrick Bernardelli

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-17

Filing date

2005-04-05

Publication date

2005-04-05

2005-04-05 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2005-04-05 Publication of NO20051695L publication Critical patent/NO20051695L/no

Links

229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title abstract 2
239000002571 phosphodiesterase inhibitor Substances 0.000 title abstract 2
AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
239000003814 drug Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)

NO20051695A 2002-09-17 2005-04-05 Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer NO20051695L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP20020292275 EP1400244A1 (en)	2002-09-17	2002-09-17	New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
PCT/IB2003/003965 WO2004026818A1 (en)	2002-09-17	2003-09-08	New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number	Publication Date
NO20051695L true NO20051695L (no)	2005-04-05

Family

ID=31896987

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051695A NO20051695L (no)	2002-09-17	2005-04-05	Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer

Country Status (30)

Country	Link
US (1)	US7429598B2 (is)
EP (2)	EP1400244A1 (is)
JP (1)	JP2006501277A (is)
KR (1)	KR20050057371A (is)
CN (1)	CN1681507A (is)
AP (1)	AP2005003251A0 (is)
AR (1)	AR041271A1 (is)
AU (1)	AU2003259496A1 (is)
BR (1)	BR0314379A (is)
CA (1)	CA2499330C (is)
CO (1)	CO5540391A2 (is)
CR (1)	CR7728A (is)
EA (1)	EA200500312A1 (is)
EC (1)	ECSP055671A (is)
GT (1)	GT200300201A (is)
HN (1)	HN2003000285A (is)
HR (1)	HRP20050223A2 (is)
IS (1)	IS7700A (is)
MA (1)	MA27439A1 (is)
MX (1)	MXPA05002913A (is)
NO (1)	NO20051695L (is)
OA (1)	OA12924A (is)
PA (1)	PA8582801A1 (is)
PE (1)	PE20050073A1 (is)
PL (1)	PL375977A1 (is)
TN (1)	TNSN05073A1 (is)
TW (1)	TWI251590B (is)
UY (1)	UY27986A1 (is)
WO (1)	WO2004026818A1 (is)
ZA (1)	ZA200501381B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003237532B2 (en)	2002-06-12	2009-07-30	Symphony Evolution, Inc.	Human ADAM-10 inhibitors
GB0504209D0 (en) *	2005-03-01	2005-04-06	Pfizer Ltd	New use of PDE7 inhibitors
WO2006092692A1 (en) *	2005-03-01	2006-09-08	Pfizer Limited	Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
EP1855686A1 (en) *	2005-03-01	2007-11-21	Pfizer Limited	Use of pde7 inhibitors for the treatment of neuropathic pain
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
WO2007063391A2 (en)	2005-12-02	2007-06-07	Pfizer Limited	Spirocyclic quinazoline derivatives as pde7 inhibitors
CA2640678C (en)	2006-02-03	2015-03-31	Bionomics Limited	Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
MX2009010450A (es)	2007-03-27	2009-11-23	Omeros Corp	El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
US8637528B2 (en)	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
CA2687944A1 (en) *	2007-05-24	2008-11-27	Pfizer Limited	Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
EP2167497A2 (en) *	2007-06-29	2010-03-31	Sunesis Pharmaceuticals, Inc.	Heterocyclic compounds useful as raf kinase inhibitors
CL2008001933A1 (es)	2007-06-29	2009-09-25	Millennium Pharm Inc	Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
HUE035295T2 (en) *	2008-08-06	2018-05-02	Medivation Technologies Inc	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CA2787844C (en)	2010-02-03	2019-08-27	Biomarin Pharmaceutical Inc.	Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
US20110190266A1 (en) *	2010-02-04	2011-08-04	Daniel Chu	5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
MX340319B (es)	2010-02-08	2016-07-06	Medivation Technologies Inc	Procesos para sintetizar derivados de dihidropiridoftalazinona.
CN103282365B (zh)	2010-10-21	2017-12-29	麦迪韦逊科技有限公司	结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR102385359B1 (ko)	2010-11-08	2022-04-11	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use
US11685745B2 (en)	2017-07-12	2023-06-27	Dart Neuroscience, Llc	Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
CN112574202B (zh) *	2020-12-11	2021-11-09	台州学院	一种螺喹唑啉-2-酮类衍生物及其制备方法和应用
CA3264513A1 (en)	2022-08-18	2024-02-22	Mitodicure Gmbh	USE OF SUBSTITUTED BENZOFURAN AND BENZOXAZOLE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERCISE INTOLERANCE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5959685A (ja) *	1982-09-28	1984-04-05	Kyowa Hakko Kogyo Co Ltd	新規なピペリジン誘導体
JPS5959865A (ja) *	1982-09-30	1984-04-05	Ube Ind Ltd	耐熱鋳鋼
US4906630A (en) *	1985-11-22	1990-03-06	Rorer Pharmaceutical Corporation	Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds
US4666913A (en) *	1985-11-22	1987-05-19	William H. Rorer, Inc.	Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses
US4764512A (en) *	1986-08-27	1988-08-16	Rorer Pharmaceutical Corporation	Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
US5102886A (en)	1990-10-12	1992-04-07	American Home Products Corporation	1'-aminospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
IL102764A0 (en) *	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
WO2000066560A1 (en)	1999-05-04	2000-11-09	American Home Products Corporation	Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2002076953A1 (en) *	2001-03-21	2002-10-03	Warner-Lambert Company Llc	New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6596167B2 (en)	2001-03-26	2003-07-22	Koch Membrane Systems, Inc.	Hydrophilic hollow fiber ultrafiltration membranes that include a hydrophobic polymer and a method of making these membranes

2002
- 2002-09-17 EP EP20020292275 patent/EP1400244A1/en not_active Withdrawn
2003
- 2003-09-08 KR KR1020057004511A patent/KR20050057371A/ko not_active Ceased
- 2003-09-08 WO PCT/IB2003/003965 patent/WO2004026818A1/en not_active Ceased
- 2003-09-08 HR HR20050223A patent/HRP20050223A2/hr not_active Application Discontinuation
- 2003-09-08 AP AP2005003251A patent/AP2005003251A0/xx unknown
- 2003-09-08 CN CNA038221284A patent/CN1681507A/zh active Pending
- 2003-09-08 AU AU2003259496A patent/AU2003259496A1/en not_active Abandoned
- 2003-09-08 OA OA1200500073A patent/OA12924A/en unknown
- 2003-09-08 JP JP2004537412A patent/JP2006501277A/ja not_active Withdrawn
- 2003-09-08 MX MXPA05002913A patent/MXPA05002913A/es active IP Right Grant
- 2003-09-08 CA CA 2499330 patent/CA2499330C/en not_active Expired - Fee Related
- 2003-09-08 BR BR0314379A patent/BR0314379A/pt not_active IP Right Cessation
- 2003-09-08 EA EA200500312A patent/EA200500312A1/ru unknown
- 2003-09-08 PL PL37597703A patent/PL375977A1/xx not_active Application Discontinuation
- 2003-09-08 EP EP20030797455 patent/EP1542694A1/en not_active Withdrawn
- 2003-09-16 AR ARP030103355 patent/AR041271A1/es unknown
- 2003-09-16 TW TW92125477A patent/TWI251590B/zh not_active IP Right Cessation
- 2003-09-16 PA PA8582801A patent/PA8582801A1/es unknown
- 2003-09-16 PE PE2003000943A patent/PE20050073A1/es not_active Application Discontinuation
- 2003-09-17 US US10/667,111 patent/US7429598B2/en not_active Expired - Fee Related
- 2003-09-17 GT GT200300201A patent/GT200300201A/es unknown
- 2003-09-17 HN HN2003000285A patent/HN2003000285A/es unknown
- 2003-09-17 UY UY27986A patent/UY27986A1/es not_active Application Discontinuation
2005
- 2005-02-16 ZA ZA200501381A patent/ZA200501381B/xx unknown
- 2005-02-17 IS IS7700A patent/IS7700A/is unknown
- 2005-03-10 CR CR7728A patent/CR7728A/es not_active Application Discontinuation
- 2005-03-11 EC ECSP055671 patent/ECSP055671A/es unknown
- 2005-03-16 CO CO05024530A patent/CO5540391A2/es not_active Application Discontinuation
- 2005-03-17 TN TNP2005000073A patent/TNSN05073A1/fr unknown
- 2005-03-17 MA MA28153A patent/MA27439A1/fr unknown
- 2005-04-05 NO NO20051695A patent/NO20051695L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
PA8582801A1 (es)	2004-05-26
TNSN05073A1 (fr)	2007-05-14
US20040106631A1 (en)	2004-06-03
KR20050057371A (ko)	2005-06-16
CA2499330C (en)	2009-04-28
MA27439A1 (fr)	2005-07-01
WO2004026818A1 (en)	2004-04-01
MXPA05002913A (es)	2005-05-27
HRP20050223A2 (en)	2005-10-31
US7429598B2 (en)	2008-09-30
CR7728A (es)	2005-06-08
ECSP055671A (es)	2005-05-30
EP1400244A1 (en)	2004-03-24
EP1542694A1 (en)	2005-06-22
ZA200501381B (en)	2006-11-29
IS7700A (is)	2005-02-17
OA12924A (en)	2006-10-13
CN1681507A (zh)	2005-10-12
EA200500312A1 (ru)	2005-08-25
UY27986A1 (es)	2004-04-30
PL375977A1 (en)	2005-12-12
GT200300201A (es)	2004-05-18
JP2006501277A (ja)	2006-01-12
CO5540391A2 (es)	2005-07-29
BR0314379A (pt)	2005-07-19
CA2499330A1 (en)	2004-04-01
AU2003259496A1 (en)	2004-04-08
AR041271A1 (es)	2005-05-11
PE20050073A1 (es)	2005-02-28
AP2005003251A0 (en)	2005-03-31
TWI251590B (en)	2006-03-21
HN2003000285A (es)	2004-11-23
TW200413333A (en)	2004-08-01

Legal Events

Date	Code	Title	Description
2008-04-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
SE0202463D0 (sv)	2002-08-14	Novel compounds
ATE433981T1 (de)	2009-07-15	Heterocyclische verbindungen
UA84878C2 (ru)	2008-12-10	Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения
NO20070570L (no)	2007-04-10	Forbindelser.
JO2353B1 (en)	2006-12-12	New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
NO20050828L (no)	2005-04-05	lndol-3-svovelderivater
ATE394383T1 (de)	2008-05-15	Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
NO20025601L (no)	2003-01-06	Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20045369L (no)	2004-12-08	Nye, substituerte sulfamatanticonvulsivaderivater
CA2499330A1 (en)	2004-04-01	New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
MY141739A (en)	2010-06-15	Substituted quinazoline derivatives as inhibitors of aurora kinases
MY144655A (en)	2011-10-31	Pyrimidine urea derivatives as kinase inhibitors
NO20030301L (no)	2003-03-11	Nye heteroarylderivater og anvendelse derav som farmasöytika
NO20054329L (no)	2005-11-21	Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
WO2001032654A3 (fr)	2001-09-27	Nouveaux composes heterocycliques et leur application a titre de medicaments
BRPI0413094A (pt)	2006-10-03	derivados de quinolina e seu uso em terapia
WO2004100865A3 (en)	2005-01-20	New benzimidazole derivatives
GB0308201D0 (en)	2003-05-14	Novel compounds
NO20052683L (no)	2005-06-03	Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
UA86776C2 (ru)	2009-05-25	Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0400850D0 (sv)	2004-03-31	Novel Compounds
SE0300908D0 (sv)	2003-03-31	Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2004014868A3 (en)	2004-06-03	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA04009476A (es)	2005-01-25	Compuestos de (tiazol-4,2-disustituidos-5-il)amina como inhibidores de la pde7.
GB0109122D0 (en)	2001-05-30	Novel compounds